IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF
Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.Peer-Reviewed Original ResearchMeSH KeywordsHeart FailureHumansInsulin-Like Growth Factor Binding ProteinsProportional Hazards ModelsStroke VolumeVentricular Dysfunction, LeftConceptsInsulin-like growth factor-binding protein 7IGFBP-7 levelsHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHigh-sensitivity troponin TCox proportional hazards modelBenefit of dapagliflozinDAPA-HF trialEjection fraction (EF) findingsIGFBP-7 concentrationsWorse clinical profileReduced ejection fractionAdverse clinical outcomesPotential prognostic biomarkerProportional hazards modelAdvanced HFrEFDAPA-HFCardiovascular deathHF outcomesNT-proBNPPrimary endpointClinical profileEjection fractionHighest tertile